PROTON PUMP INHIBITORS IN THE TREATMENT OF PEDIATRIC GERD: SAFETY CONCERNS

Pulatov Firdavs Abdunabiyevich
3rd-year student, Faculty of Pharmacy, Samarkand State Medical University
+998902289830 / firdavspulatov555@gmail.com
Ruzikulov Xumoyunbek Quyli o‘g‘li
3rd-year student, Faculty of Pediatrics, Samarkand State Medical University
+998979301170 / khumoyun2006@icloud.com
Ne’matullayev Temurbek Baxodirovich
4th-year student, Faculty of Pediatrics, Samarkand State Medical University
+998 93 309 31 03 / nematullaevtemurbek@gmail.com
Samarkand, Uzbekistan

Abstract: *Gastroesophageal reflux disease (GERD) is a common gastrointestinal disorder in children, characterized by the retrograde flow of gastric contents into the esophagus, leading to symptoms such as regurgitation, heartburn, feeding difficulties, and, in severe cases, esophagitis. Proton pump inhibitors (PPIs) are widely used as first-line pharmacological therapy due to their potent acid-suppressive effects, demonstrated efficacy in symptom relief, and promotion of esophageal mucosal healing. However, increasing evidence has raised concerns regarding the safety profile of PPIs in pediatric populations, particularly with long-term use. Potential adverse effects include alterations in gut microbiota, increased risk of gastrointestinal infections, nutrient malabsorption, bone mineral density reduction, and rare but serious renal complications. Clinical studies emphasize the importance of weighing therapeutic benefits against potential risks, tailoring PPI use to appropriate indications, and monitoring treatment duration. This review synthesizes current evidence on the safety considerations of PPI therapy in children with GERD, highlighting the need for judicious prescription, vigilant monitoring, and exploration of alternative or adjunctive strategies. Understanding these safety issues is essential to optimizing clinical outcomes while minimizing unintended consequences in the pediatric population.*

Keywords: *Gastroesophageal reflux disease, GERD, children, proton pump inhibitors, PPI safety, adverse effects, pediatric gastroenterology, acid suppression therapy*

Introduction: Gastroesophageal reflux disease (GERD) is a prevalent condition in the pediatric population, characterized by the retrograde movement of gastric contents into the esophagus, resulting in a spectrum of clinical manifestations ranging from mild regurgitation to severe esophagitis. In children, GERD can interfere with growth, feeding, and overall quality of life, and, if untreated, may lead to complications such as

esophageal strictures, Barrett's esophagus, and chronic respiratory symptoms.

Proton pump inhibitors (PPIs) are the mainstay of pharmacological therapy due to their potent acid-suppressive effects, rapid symptom relief, and ability to promote esophageal mucosal healing. These agents inhibit the H+/K+ ATPase enzyme in gastric parietal cells, effectively reducing gastric acid secretion, which is central to the pathophysiology of GERD.

Despite their proven efficacy, the long-term safety of PPI therapy in children has become a growing concern. Recent clinical and epidemiological studies have reported potential associations between prolonged PPI use and adverse outcomes, including increased susceptibility to gastrointestinal infections such as Clostridioides difficile, alterations in gut microbiota, nutrient malabsorption (including magnesium, calcium, and vitamin B12), and decreased bone mineral density. Rare but serious complications, such as acute interstitial nephritis and chronic kidney disease, have also been documented. These findings underscore the need for careful evaluation of indications, dosing, and treatment duration in pediatric patients.

Evidence-based guidelines recommend that PPIs should be prescribed only when clearly indicated, such as in cases of erosive esophagitis, confirmed pathologic acid reflux, or persistent symptoms unresponsive to lifestyle modification and conservative management. Additionally, regular monitoring and reassessment of clinical response and potential adverse effects are essential to ensure both efficacy and safety. The balance between therapeutic benefits and potential risks is particularly important in infants and young children, whose developing organ systems may be more vulnerable to pharmacological interventions.

Given the increasing recognition of safety concerns associated with PPI therapy, there is a critical need to understand the mechanisms underlying adverse effects, identify high-risk patient populations, and develop strategies to mitigate risks while maintaining clinical effectiveness. This review aims to examine current evidence regarding the safety of PPIs in children with GERD, discuss potential adverse outcomes, and provide guidance for optimized, judicious clinical use.

Main part: Proton pump inhibitors (PPIs) are widely recognized as the most potent pharmacological agents for the suppression of gastric acid, making them central to the management of gastroesophageal reflux disease (GERD) in pediatric populations. Their mechanism of action involves selective, irreversible inhibition of the H+/K+ ATPase enzyme in gastric parietal cells, resulting in sustained reduction of gastric acid secretion. This property allows for rapid symptom relief, healing of esophageal mucosa, and improved quality of life in affected children. Despite these therapeutic benefits, emerging evidence has highlighted a range of safety concerns associated with short-term and long-term PPI therapy, particularly in infants, toddlers, and children with comorbid conditions.

Short-term PPI administration is generally well-tolerated, with adverse effects being mild and transient, such as headache, nausea, abdominal discomfort, and diarrhea.

However, with prolonged use, alterations in gastrointestinal physiology become more pronounced. One key concern is the impact of acid suppression on the gut microbiota. Gastric acid serves as a primary barrier to ingested pathogens; its suppression can facilitate bacterial overgrowth and dysbiosis, increasing susceptibility to infections such as Clostridioides difficile, community-acquired pneumonia, and gastroenteritis. Clinical studies have demonstrated that children on prolonged PPI therapy exhibit higher incidence rates of these infections compared to untreated peers, underscoring the importance of limiting therapy duration and employing targeted indications.

Another critical safety consideration involves nutrient absorption. Gastric acidity plays a crucial role in the bioavailability of several essential micronutrients, including calcium, magnesium, iron, and vitamin B12. Long-term acid suppression may impair the absorption of these nutrients, potentially affecting bone mineralization, neuromuscular function, and hematologic status. Observational studies in pediatric populations have suggested associations between chronic PPI use and decreased bone mineral density, increased fracture risk, and hypomagnesemia, although the absolute risk remains low when therapy is appropriately monitored. These findings emphasize the need for regular nutritional assessment, monitoring of serum electrolytes, and consideration of supplementation in at-risk children.

Renal and systemic complications, while rare, are increasingly recognized in the context of long-term PPI therapy. Case reports and retrospective studies have documented instances of acute interstitial nephritis, chronic kidney disease, and electrolyte imbalances in children receiving prolonged treatment. Mechanisms are thought to involve immune-mediated injury and altered renal handling of electrolytes secondary to chronic acid suppression. As such, clinicians are advised to monitor renal function and electrolyte status periodically, especially in children with pre-existing renal or metabolic disorders.

The appropriateness of PPI prescription is also influenced by age and developmental stage. Infants and young children are particularly vulnerable due to immature renal and hepatic systems, heightened sensitivity to metabolic alterations, and greater reliance on optimal nutrient absorption for growth and development. Overprescription in this group, often for non-erosive reflux or physiological regurgitation, has been documented in clinical practice, highlighting the need for stringent diagnostic criteria, evidence-based prescribing, and ongoing reassessment of therapeutic necessity. Non-pharmacological interventions, including feeding modification, positional therapy, and dietary adjustments, should be prioritized where feasible to minimize unnecessary exposure to acid suppression therapy.

Evidence-based clinical guidelines emphasize that PPIs should be reserved for clearly indicated scenarios, such as confirmed erosive esophagitis, severe or refractory GERD symptoms, or complications like esophageal strictures. Therapy should be time-limited, with the lowest effective dose used, and reassessment conducted periodically to

determine the continued need for acid suppression. Intermittent therapy or step-down approaches may be considered in children requiring prolonged treatment to reduce potential risks. Education of caregivers regarding medication adherence, potential adverse effects, and recognition of early signs of complications is integral to safe and effective therapy.

Recent research also explores the broader systemic effects of prolonged PPI use, including alterations in immune function, gut-brain axis modulation, and potential metabolic consequences. While the majority of adverse events are mild, the cumulative evidence suggests that even subtle disruptions in gut microbiota or nutrient absorption during critical periods of growth can have long-term implications. Consequently, individualized therapy, careful monitoring, and adherence to evidence-based guidelines remain essential pillars in pediatric GERD management.

In conclusion, while PPIs remain highly effective for the management of GERD in children, their safety profile warrants careful consideration. Clinicians must balance therapeutic benefits with potential risks, employing judicious prescribing practices, ongoing monitoring, and incorporation of non-pharmacological strategies. Optimizing PPI therapy in children requires a comprehensive understanding of age-specific pharmacodynamics, risk factors for adverse effects, and strategies to minimize long-term complications, ensuring both efficacy and safety in this vulnerable population.

Conclusion and clinical recommendations: Proton pump inhibitors (PPIs) are a cornerstone in the management of pediatric gastroesophageal reflux disease (GERD) due to their potent acid-suppressive effects and proven efficacy in symptom relief and esophageal mucosal healing. However, increasing evidence highlights potential safety concerns associated with their use in children, particularly during prolonged therapy. Adverse effects may include alterations in gut microbiota, increased susceptibility to gastrointestinal and respiratory infections, impaired nutrient absorption, reductions in bone mineral density, and rare renal complications. Recognition of these risks underscores the importance of judicious prescribing, individualized dosing, and vigilant monitoring.

Clinical recommendations for optimizing safety and efficacy in pediatric PPI therapy include:

1. **Strict indication adherence**: PPIs should be reserved for confirmed pathological GERD, erosive esophagitis, or complications unresponsive to conservative management.
2. **Individualized dosing**: Therapy should consider the child's age, weight, severity of disease, and comorbid conditions, using the lowest effective dose.
3. **Limited duration of therapy**: Treatment should be time-limited whenever possible, with periodic reassessment to determine the ongoing need for acid suppression.
4. **Monitoring for adverse effects**: Regular evaluation of growth, serum electrolytes, renal function, and bone health is recommended, especially for long-term therapy.

5. **Integration of non-pharmacological strategies**: Feeding modifications, positional therapy, and dietary adjustments should be incorporated to reduce reliance on prolonged PPI use.

6. **Parental and caregiver education**: Informing families about proper administration, potential side effects, and signs of complications enhances adherence and early recognition of adverse events.

7. **Step-down or intermittent therapy**: In cases requiring extended treatment, dose reduction or intermittent regimens may help minimize risks while maintaining clinical efficacy.

8. **Research-informed clinical decisions**: Clinicians should remain updated on emerging evidence regarding PPI safety, microbiota alterations, and systemic effects in children.

By applying these recommendations, clinicians can achieve effective GERD management while minimizing potential complications, ensuring safe and evidence-based care for pediatric patients. A comprehensive approach combining judicious pharmacological use, ongoing monitoring, and supportive interventions provides the foundation for optimal long-term outcomes in children with GERD.

REFERENCES

1. Vandenplas Y., Rudolph C.D., Di Lorenzo C. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of NASPGHAN and ESPGHAN. J Pediatr Gastroenterol Nutr, 2009; 49(4): 498–547.

2. Hassall E. Long-term safety of proton pump inhibitors in children. Aliment Pharmacol Ther, 2008; 28(9): 1040–1053.

3. Freedberg D.E., Kim L.S., Yang Y.X. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology, 2017; 152(4): 706–715.

4. Kearns G.L., Abdel-Rahman S.M., Alander S.W. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med, 2003; 349: 1157–1167.

5. Guillet R., Stoll B., Salhab W. Effect of proton pump inhibitors on the risk of necrotizing enterocolitis in preterm infants. J Pediatr, 2006; 148: 364–369.

6. Lucendo A.J., Miehlke S., Eliakim R. Management of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia in children. J Pediatr Gastroenterol Nutr, 2017; 64: 93–103.

7. Omari T.I., Davidson G.P. Pathophysiology and clinical implications of gastroesophageal reflux in children. Neurogastroenterol Motil, 2003; 15: 141–149.

8. Canani R.B., Cirillo P., Terrin G. Therapy with proton pump inhibitors and risk of enteric infections in pediatric populations. J Pediatr Gastroenterol Nutr, 2007; 45: 296–299.

9. Freedberg D.E., Kim L.S., Yang Y.X. The risks and benefits of long-term use of proton pump inhibitors. Nat Rev Gastroenterol Hepatol, 2017; 14: 74–80.

10. Malaty H.M., Graham D.Y. Gastroesophageal reflux disease in children: pathophysiology, diagnosis, and treatment. Curr Gastroenterol Rep, 2004; 6: 13–20.

11. Hommel K., Bjerregaard A., Andersen A.S. Effects of proton pump inhibitors on calcium absorption and bone mineral density in pediatric patients. Pediatr Drugs, 2011; 13: 179–188.

12. Hassall E. The long-term safety of proton pump inhibitors in children. Paediatr Drugs, 2009; 11: 17–28.

13. Penders J., Thijs C., Vink C. Gut microbiota composition and diversity in children treated with proton pump inhibitors. PLoS One, 2013; 8(2): e64370.

14. Saper R.B., Eisenberg D.M., Davis R.B. Prevalence and safety of long-term proton pump inhibitor use in pediatric populations. Arch Pediatr Adolesc Med, 2004; 158: 761–765.

15. Roberts R.L., Duffy S., Miller M.A. Proton pump inhibitors and risk of Clostridium difficile infection in children. Pediatr Infect Dis J, 2007; 26: 897–900.

16. Lucendo A.J., Molina-Infante J., Arias Á. Updated international consensus on pediatric GERD and proton pump inhibitor safety. Clin Gastroenterol Hepatol, 2016; 14: 1200–1214.